Environmental Impact Acquisition Corp.
Environmental Impact Acquisition — SPAC Merger (January 2022)
58 slides from Environmental Impact Acquisition's SPAC merger presentation, Jan 21, 2022
Slide 1: Analyst teach-in part II January 2022
Analyst teach-in part II January2022 Filed by Environmental Impact Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Environmental Impact Acquisition Corp. Commission File No. 001-3
Slide 2: Welcome to our teach-in
Today’s teach-in aims to update analysts on the company’s progress toward solving some of the world’s largest and most difficult problems by delivering on the full potential of RNA. Welcome to our teach-in Analyst teach-in 1 in December 2021 covered: Company overview Platform Human health Analyst te
Slide 3: What if we could make RNA accessible to everyone?
What if we could make RNA accessible to everyone?
Slide 4: Disclaimer: Caution Regarding Forward Looking Statements
Disclaimer Caution Regarding Forward Looking Statements Certain statements included in this Investor Presentation (“Presentation”) that are not historical facts are forward-looking statements for purposes of US law. Forward-looking statements generally are accompanied by words such as “believe,” “ma
Slide 5: Disclaimer: Use of projections
Disclaimer Use of projections This Presentation contains projected financial information with respect to GreenLight. Such projected financial information constitutes forward-looking information and is for illustrative purposes only. Financial projections should not be relied upon as necessarily bein
Slide 6: Disclaimer: Trademarks and participants in the solicitation
Disclaimer Trademarks All trademarks, service marks, and trade names of Environmental Impact Acquisition Corporation ("ENVI") or GreenLight or their respective affiliates used herein are trademarks, service marks, or registered trade names of Environmental Impact Acquisition Corporation ("ENVI") or
Slide 7: Company overview
Andrey cover slide Need image Andrey Zarur Company overview
Slide 8: GreenLight has a clear purpose
We aim to achieve this goal through the design, development and production of RNA through our unique cell-free biomanufacturing platform including the know-how around it. This platform enables us to make complex biological molecules in a manner that we believe is capable of creating products at a lo
Slide 9: Global partnerships enable vaccinations for low- and middle-income countries
[image of world map with dots on partners’ locations] Serum Institute of India: [Pune, India] Discovery & pre-clinical development cGMP mRNA manufacturing Regional commercialization Targets: chronic hepatitis B, HIV, and bladder cancer Eva Pharma [Giza, Egypt] Commercialization in Africa and the Mid
Slide 10: Humanity faces numerous challenges
Humanity faces numerous challenges. There are more than seven and a half billion people sharing the diminishing resources of Earth. This growing population needs to produce more food with the same amount of land and, at the same time, honor the global desire to replace chemical pesticides. Not only
Slide 11: RNA has gained broad global prominence
Ribonucleic acid, or RNA, has gained broad global prominence as the COVID-19 pandemic has swept through the world’s population, prompting messenger RNA, or mRNA, vaccines to move from a scientific theory to a medical reality. Vaccines made using mRNA proved among the fastest to develop and the easie
Slide 12: Technology platform for dsRNA and mRNA production
Our technology platform, which was initially developed to produce dsRNA molecules for agricultural crop protection solutions and is protected by patents and know-how, is capable of synthesizing building blocks (nucleotides), building tools (enzymes), and instructions (DNA templates) to make dsRNA wi
Slide 13: GreenLight's vision
Create Solutions to major challenges facing humanity through the rigorous application of biological sciences Deliver Innovative RNA-based products for sustainable food production and human health, with our breakthrough synthetic biology platform Reward Our shareholders, employees, and stakeholders b
Slide 14: GreenLight exists to bring RNA solutions to pressing challenges
We will be 9 billion humans on earth by 2037, increasingly adopting a middle-class lifestyle. For survival of humanity and the planet, our diets must be less carbon-intense. We must stop clearing land and reduce our use of chemical pesticides and fertilizers. We must end this pandemic, prepare for t
Slide 15: IP and collaborations
i " | IP and collabora a ~ a ~~
Slide 16: Exceptional management team
Exceptional management team with diverse public company expertise and proven track record of success Our team Andrey J. Zarur Ph.D CEO Charu Manocha MBA CPO Susan Keefe MBA CFO Thomas Crampton SVP & Head Corporate Affairs Carole Cobb MBA COO David Kennedy General Counsel Marta Ortega-Valle MBA CBO H
Slide 17: Extensive and rapidly expanding IP portfolio
Extensive and rapidly expanding IP portfolio 145+ patents and 165+ applications RNA Platform Foundational U.S. Patents 2 1 Foundational Japan Patent 61 Foundational Apps 10 Improvement Apps Process Control and Compound Production 53 Patents 9 Applications Human Health mRNA Platform App; RNA Gene The
Slide 18: Our Life Sciences advisors
Our Life Sciences advisors Luc Debruyne Former President GSK Global Vaccines Dr. Mark Dybul Former Exec Dir Global Fund Dr. Ted Ashburn Pres and CEO Oncorus Diane Griffin VP US National Academy of Sciences Dr Emmanuel Hannon Ex SVP GSK Vaccines
Slide 19: Our collaborators
Our collaborators B @ & Oo. TT @ R ACUITAS — “ramacttnene SAMSUNG BIOLOGICS WISCONSIN ZZ Fraunhofer
Slide 20: Investors
Investors & SERUM. INSTITUTE. OF INDIA alla Gr Baird Capital Pn Fall Line Capital s2dventures = F 3 HR BOEETEnues Lupa Systems x Continental. Cormorant 75) CGC canon
Slide 21: GreenLight's vision
Create Solutions to major challenges facing humanity through the rigorous application of biological sciences Deliver Innovative RNA-based products for sustainable food production and human health, with our breakthrough synthetic biology platform Reward Our shareholders, employees, and stakeholders b
Slide 22: GreenLight exists to bring RNA solutions to pressing challenges
We will be 9 billion humans on earth by 2037, increasingly adopting a middle-class lifestyle. For survival of humanity and the planet, our diets must be less carbon-intense. We must stop clearing land and reduce our use of chemical pesticides and fertilizers. We must end this pandemic, prepare for t
Slide 23: Why invest in us?
Why invest in us? 1 Cutting edge, proven technology to democratize RNA, making it available to solve problems in the world’s most important markets: Agriculture, Food Production and Health Synthetic biology platform capable of producing RNA at scale, underscoring power of manufacturing at scale with
Slide 24: Plant health presentation
Plant health presentation Mark Singleton
Slide 25: Product launches by 2026 and addressable markets
7 Product Launches by 2026 $6B 2026E Addressable Markets High-priority geographies for xxx x x x x xxxxx CPB Potatoes Pollinator Bee hives Botrytis Most fruit and vegetables DBM Cabbage Fusarium Wheat TSSM Most fruit and vegetables Global product portfolio addresses key food and agriculture industry
Slide 26: History of pest and crop protection
2500 BC 1200 BC 500 BC 1 AD 1100 1800 1900 1940s 1962 1974 1980s 1990s 5500 BC 8000 BC 2000s Hunter gathering begins Plant ‘domestication’ Sumerians use sulphur to control insects and mites Chinese use Arsenic for body lice control Principles of irrigation, fertilization and crop rotations emerge Ro
Slide 27: A market that demands innovation isn't getting much of it
140 120 100 80 60 40 20 0 140 120 100 80 60 40 20 0 1950s 1960s 1970s 1980s 1990s 2000s 2010s Herbicides Insecticides Fungicides Others Source: CropLife America A market that demands innovation isn’t getting much of it Farmers and consumers are not currently getting what they need Number of new acti
Slide 28: Diminishing set of effective and acceptable tools
Diminishing set of effective and acceptable tools leave farmers and consumers seeking new solutions RNA offers a highly favorable regulatory profile due to targeted design and low toxicity RNA degrades quickly in the environment and in many cases low/no residue 3 ‘R’s: Resistance, residues, and regu
Slide 29: History of pest and crop protection
2500 BC 1200 BC 500 BC 1 AD 1100 1800 1900 1940s 1962 1974 1980s 1990s 5500 BC 8000 BC 2000s 2022 Hunter gathering begins Plant ‘domestication’ Sumerians use sulphur to control insects and mites Chinese use Arsenic for body lice control Principles of irrigation, fertilization and crop rotations emer
Slide 30: Delivering dsRNA to control Colorado potato beetle
Mixed with water and sprayed using standard agricultural practice over crops, the RNA is used at a rate of a few grams per hectare. This is less than one-tenth the rate at which most conventional industrial chemicals are normally used on fields. Consumption of the RNA causes the Colorado potato beet
Slide 31: Pipeline stretches across a $10bn addressable market
Program Collaborator Discovery & lab studies Greenhouse trials Confirmatory trials POC field trials Regulatory submission Launch year TAM($M) Colorado Potato Beetle 2022 $350 Varroa Mite 2024 $290 Botrytis 2025 $1,200 Powdery Mildew * 2025 $1,400 Diamondback Moth 2025 $890 Fusarium * 2025 $950 Two S
Slide 32: Meets farmers' buying criteria
Untreated, 30 days 9.9 g of GreenLight RNA per hectare Meets farmers’ buying criteria Equivalent efficacy to existing chemical-based treatments Cost competitive to other premium solutions Compatible with farmers’ standard operating procedures Low risk for operators and consumers Low to no detectable
Slide 33: We developed CPB quickly
We developed CPB quickly; industry typically takes 10+ years 2017 Today Achieved active ingredient specifications & cost target with commercially viable process RNA process proof of concept IP filed Analytical methods established Sequences evaluated for 1st product Process scaled First green house &
Slide 34: Screening platform broadens pipeline
Screening platform broadens pipeline by helping identify and select best triggers Identify Bioinformatics Tools such as machine learning and proprietary algorithms identify best gene target candidates to protect food crops, design advanced medicines and vaccines for human and animal health Develop a
Slide 35: Machine learning supports dsRNA sequence design
Machine learning supports dsRNA sequence design Goal is to find sequences that affect growth, normal cell function, or prevent infection or colonization of the host plant Designs are created using our algorithm which looks at 30 features Sequence features Structural features Thermodynamic features H
Slide 36: Machine learning supports dsRNA sequence design
Goal is to find sequences that affect growth, normal cell function, or prevent infection or colonization of the host plant Machine learning supports dsRNA sequence design Transcript from target gene of interest Get a subsequence without any hits to Non-Target Organisms Predict Silencing Efficacy Con
Slide 37: Cell-free allows low-cost, larger-scale production
Cell-free allows for low-cost, larger-scale production of lead candidates for greenhouse tests, formulation development, etc. Robotic high-throughput production allows screening of up to 1,000+ initial candidates Robotic high-throughput production for all candidates Cell-free production for lead can
Slide 38: Candidates narrowed through screening
10.3% of candidates Botrytis in vitro and 9.9% of candidates in vivo attained target threshold to advance In vivo screening 191 candidate sequences screened 9.9% attained target threshold 19 nominated for greenhouse testing In vitro screening 969 candidate sequences screened 10.3% attained target th
Slide 39: Candidates optimized for each crop
Successful candidates are optimized for each crop in terms of formulation and rate definition Whole plant screening Formulation testing Two initial rates are selected per hit for screening on tomato plants and strawberries Rate definition Development: Greenhouse screens for efficacy of dsRNA on whol
Slide 40: Field development program for grape powdery mildew
Formulated dsRNA is optimized for the lowest use rate that delivers viable potency and persistence GreenLight field development program translates lab success into tested solutions Grape powdery mildew (PM) caused by Erysiphe necator is economically important in the global crop protection market. O
Slide 41: Control equivalent to commercial standards
GreenLight sequence demonstrates control equivalent to commercial standards First-of-a-kind fungicidal activity seen in GreenLight field trials % Disease severity of Powdery Mildew on grapes Treatments applied every 3-4 days (twice/week) or every 7 days (once/week) throughout season Data taken 48 da
Slide 42: RNA sequences show promise in New York field trials
RNA sequences show promise against disease in New York field trials Low use rate of GL43 on Erysiphe necator demonstrates control equivalent to commercial standards Trial Location: Dundee, New York Trial: June 8 - July 30 application window; weekly assessments Disease incidence – % of leaves that sh
Slide 43: Field efforts turn one trigger into multiple solutions
Non-formulated and formulated dsRNA optimized for the lowest use rate that delivers viable potency and persistence Field efforts can also turn one trigger into multiple solutions for a farmer Gene Target Selection Robotic High-Throughput Production In vitro screening & MOA confirmation In vivo scree
Slide 44: GreenLight's first field trial with honeybees
GreenLight’s first field trial with honeybees
Slide 45: Honeybees are critical to almond pollination
Honeybees are critical to almond pollination Many other commercial crops are also dependent on honeybee pollination services In the U.S. commercial honeybees are known as the Western Honeybee or the European Honeybee - Apis mellifera US honeybees are responsible for the commercial pollination of alm
Slide 46: Varroa mite attacks and feeds on honeybees
The external parasitic mite attacks and feeds on honeybees Every hive in US has or will have Varroa destructor (Varroa mite) Originally only on the Eastern honeybee (Apis cerana) but now attacks the Western honeybee (Apis mellifera) Vectors diseases of many bee viruses such as deformed wing virus, a
Slide 47: Advancing our pollinator solution
We are quickly advancing our pollinator solution which is showing very promising field results 40% fewer Varroa destructor mites at 12 weeks in hives with GS15 compared with leading chemical control product 1 2 GREDEC025B 1 Control 2 Chemical control 2 GS15 2g/L 2 GS15 8g/L Hive health stays compara
Slide 48: Near-term commercial focus on the US 'smile'
We plan to focus our near-in commercial efforts on the “smile” of the US Need graphic help -- map of US with overlay highlighting “smile” in red
Slide 49: Product launches by 2026 and addressable markets
7 Product Launches by 2026 $6B 2026E Addressable Markets High-priority geographies for xxx x x x x xxxxx CPB Potatoes Pollinator Bee hives Botrytis Most fruit and vegetables DBM Cabbage Fusarium Wheat TSSM Most fruit and vegetables Global product portfolio addresses key food and agriculture industry
Slide 50: Appendix: Leadership profiles
Appendix: Leadership profiles This section created by Rob based on our research on Analyst needs.
Slide 51: Andrey J. Zarur, Ph.D, Co-founder, President & CEO
Co-founded GreenLight Bioscience in 2008, as a partner at Kodiak Venture Partners, a venture capital firm specializing in the formation of early stage information and life technology investments. Prior to joining Kodiak Venture Partners, he was founder and CEO of BioProcessors, which was sold to Sea
Slide 52: Carole Cobb, Chief Operating Officer
Carole Cobb Chief Operating Officer During Carole’s career she has held progressively more responsible positions in biotechnology with a specific focus on fermentation-based commercial manufacturing, including process development, worldwide manufacturing and global supply chain management. Previousl
Slide 53: Amin Khan, Ph.D, Chief Scientific Officer, Human Health
Amin Khan, Ph.D Chief Scientific Officer, Human Health Dr. Khan joined GreenLight in April this year from GSK’s Vaccines business where he was a member of their R&D leadership team. He headed their Technical R&D organization, and recently led Vaccines R&D Acceleration, where he was responsible for e
Slide 54: Mark Singleton, Ph.D, SVP, Plant Health
Mark Singleton, Ph.D SVP, Plant Health Joined GreenLight having worked on UPL’s integration of Arysta, assembled a world class team of scientists, and managed the building of the OpenAg Center in the Research Triangle Park, a 69,000 sq ft multi-functional R&D facility dedicated to the support of VC-
Slide 55: Appendix: Summary Risk Factors
Appendix: Summary Risk Factors
Slide 56: Summary Risk Factors
Summary Risk Factors Risks relating to the proposed business combination: Risks relating to the proposed business combination: GreenLight has a limited operating history, which makes it difficult to evaluate our current business and prospects and increases the risk of investment. We have a history o
Slide 57: Summary Risk Factors (cont'd)
Summary Risk Factors Risks relating to the proposed business combination (cont’d): The unpredictability of the spread and treatment of the SARS-CoV-2 virus and its variants could materially harm our business prospects. Intellectual property rights including patents and patent applications involve hi
Slide 58: Summary Risk Factors (cont'd)
Summary Risk Factors Risks relating to the proposed business combination (cont’d): The consummation of the merger is subject to a number of conditions and if those conditions are not satisfied or waived, the merger agreement may be terminated in accordance with its terms and the merger may not be co
Environmental Impact Acquisition — SPAC Merger (January 2022) on 6ix